CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-21 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Purchase | +700 | $28.81 | $20K | 700 |
| 2021-12-15 | AZAB MOHAMMAD Director | Exercise or conversion | +3,086 | $3.67 | $11K | 66,819 |
| 2021-12-15 | AZAB MOHAMMAD Director | Exercise or conversion · Stock Option (Right to Buy) | −3,086 | 0 | ||
| 2021-12-08 | PATOU GARY Director | Exercise or conversion | +2,057 | $3.67 | $8K | 25,630 |
| 2021-12-08 | PATOU GARY Director | Exercise or conversion · Stock Option (Right to Buy) | −2,057 | 0 | ||
| 2021-12-06 | Von Seggern Christopher Chief Commercial Officer | Purchase | +4,000 | $24.40 | $98K | 4,000 |
| 2021-11-15 | PIMSTONE SIMON N. Director | Sale | −17,557 | $31.33 | $550K | 210,186 |
| 2021-08-23 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2021-06-03 | PATOU GARY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | Svoronos Dawn Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | Hayden Michael R Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | GANNON STEVEN Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | AZAB MOHAMMAD Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | GAROFALO ELIZABETH A. Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-06-03 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2021-06-03 | AULIN SHERRY Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-05-28 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion | +12,345 | $3.76 | $46K | 29,141 |
| 2021-05-28 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −2,024 | $18.91 | $38K | 27,117 |
| 2021-05-28 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion | +13,374 | $3.85 | $51K | 40,491 |
Page 19 of 27 · 536 trades